Transgender Analysis of Nephrological Studies Focused on Renal Metrics
Starting soon
Conditions studied: Kidney Disease, Kidney Injury, Transgender Individuals
In brief
This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.
Key facts
- Study ID
- NCT07542964
- Run by
- Amsterdam UMC, location VUmc
- People needed
- 60
- Starts
- 2026-09-01
- Expected to finish
- 2028-09-01
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosed with gender dysphoria according to DSM-V
- Expected to start gender-affirming hormone treatment in the upcoming month
You may not qualify if…
- Current or prior use of gender-affirming hormone therapy
- Participation in other studies
- Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)
- Known kidney disease (eGFR < 60 ml/min; UACR > 2.5 mg/mmol)
- Diabetes mellitus
- A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease, or a previously undiagnosed arrhythmia)
- Known iodine-related allergies
- Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)
- Pregnancy
- Claustrophobia
Where it is running
- Amsterdam UMC, location VU medical centre, internal medicine — Amsterdam, North Holland, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.